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ABSTRACT 
Monocyte attachment to the endothelium and migration into the vessel intima are the initiating steps in atherogenesis. 
This is thought to be facilitated by endothelin-1 (ET-1) as a potent chemoattractant to human blood monocytes. To 
explore the presence of ET-1 receptor(s) on the monocyte, we studied the binding of ET-1 to freshly isolated human 
blood monocytes, in the laboratory of the Institute of Clinical Biochemistry, University of Bon, Germany in 1995. 
Radioligand binding studies revealed the presence of two distinct subclasses of binding sites with apparent 
dissociation constants, K s, of 10.3 pM and 3.5 nM and maximal binding capacities, B s, of 0.027 fmol and 0.63 d max
5fmol/1.5x10  cells. Using monocyte migration as a response to ET-1, and ET-1 receptor antagonists BQ-123, BQ-
18257B and IRL-1038, the presence of two ET receptor subtypes, ET  and ET , were detected. These results suggest A B
that the chemotactic stimulus introduced by ET-1 can be activated ET-1 specific receptors on the monocytes.
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IKATAN ENDOTELIN-1 PADA MONOSIT DARAH MANUSIA
ABSTRAK 
Menempelnya monosit ke permukaan endotel dan bermigrasi kedalam tunika intima merupakan langkah awal pada 
aterogenesis. Hal ini diduga diperantarai oleh peran endotelin-1 (ET-1) yang dikenal sebagai chemoattractant poten 
bagi monosit. Untuk mengungkapkan adanya reseptor ET-1 pada monosit, dilakukan penelitian ikatan ET-1 pada 
monosit yang diisolasi dari darah manusia, di laboratorium Institute of Clinical Biochemistry, Universitas Bonn, 
Jerman pada tahun 1995. Penilaian ikatan radioligand menunjukkan adanya dua subkelas berbeda dari tempat 
ikatan dengan konstanta disosiasi (K ) masing-masing 10,3 pM dan 3,5 nM, serta kapasitas ikatan maksimal (B ) d max
5masing-masing sebesar 0,027 fmol dan 0,63 fmol/1,5x10  sel. Dari hasil penilaian tingkat migrasi monosit sebagai 
respons terhadap ET-1 dengan atau tanpa beberapa antagonis reseptor ET-1, BQ-123, BQ-18257B dan IRL-1038, 
terdeteksi adanya dua subtipe reseptor ET, yaitu ET  dan ET . Hasil ini menunjukkan bahwa rangsangan kemotaksis A B
yang ditimbulkan ET-1 dapat mengaktifkan reseptor spesifik ET-1 pada monosit.
Kata kunci: Endotelin-1, monosit, ikatan-reseptor
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INTRODUCTION
Endothelin-1 (ET-1) is a potent vasoconstrictor 
peptide consisting of 21 amino acids; it was first 
1isolated from cultured porcine endothelial cells.  
Since this initial discovery, cells derived from 
many different tissues have been found to 
2 - 3synthesize and secrete the peptide.  
Subsequently, the cloning and sequencing of ET 
related genes revealed the existence of two 
4additional peptides, ET-2 and ET-3.  ETs have 
variety of biological actions and have been 
implicated in the pathogenesis of many 
5,6diseases, such as atherosclerosis.  In the latter 
disease, monocyte attachment to the 
endothelium and migration into the vessel intima 
7are the initiating steps in atherogenesis.  We 
found that ET-1 is a strong chemoattractant to 
8blood monocytes,  supportive of the role of ET-1 
in the pathogenesis of atherosclerosis. Little 
information is known regarding the presence of 
ET receptor(s) in monocyte. ETs initiate cellular 
effects and physiological actions after binding to 
cell surface membrane receptors. Changes in 
2+intracellular Ca , c-AMP, c-GMP, and activation 
of protein kinases are some of the responses 
subsequent to ligand-receptors, which is still to 
be elucidated in monocytes. The present study 
was designed to explore the occurrence of 
binding sites for ET-1 on human blood 
monocytes and to study the effect of receptor 
antagonists on monocyte migration.
MATERIALS AND METHODS
The materials used were obtained from the 
following sources: twenty four-well plates 
(Cat.No. 3047) and cell culture insert 
(Cat.No.3095) from Becton Dickinson, 
Heidelberg; NycoPrep 1068 and NycoPrep 1063 
from Nycomed Pharma, Oslo, Norway; human 
serum albumin from Behringwerke AG, Marburg; 
Dextran T-500 from Biozym Diagnostik, Hameln. 
Mayer's hemalum solution from Merck, 
Darmstadt; N-2-hydroxyethylpiperazine-N'-2- 
ethanesulfonic acid (HEPES) from Serva, 
Heidelberg; fetal calf serum and Medium RPMI 
1640 from Biochrom, Berlin; Endothelin-1 human 
(synthetic) and penicillin-streptomycin from 
125Sigma, I-ET-1 (specific radioactivity 2000 
Ci/mmol) from Amersham and endothelin 
receptor antagonist BQ-123, BE-18257B and 
IRL-1038 from Alexis Corporation, Switzerland.
Monocyte Isolation
Human monocytes were isolated from freshly 
drawn blood in EDTA (1.6 mg/mL) Monovettes 
(Sarstedt, Numrecht); details have been 
8described previously.
Binding Assay
The binding assay was done in the laboratory of 
Institute of Clinical Biochemistry, University of 
Bonn, Germany, in 1995. To determine the 
125binding of I-ET-1 to monocytes as a function of 
time, freshly isolated monocytes (150,000 
cells/100 ìL) were incubated for various lengths 
125 10of time with I-ET-1 (3 x 10 M) in the absence or 
in the presence of 1 ìM of unlabeled ET-1; the 
total volume was 200 ìL and the temperature 
0was 37 C. The microcentrifuge tube (capacity 
400 ìL, Beckman, Munich) containing the 
incubation contents were on a layer of a mixture 
of 100 ìL of silicone oil (Silicon oil AR 20: AR 
200/1:1, v/v). The incubation was terminated by 
centrifugation of the tubes at 10,000 g for 10s. 
The monocytes formed a pellet under the silicone 
oil layer. The tubes were cut at the oil level and 
the pellet was taken for measurement of 
radioactivity in a gamma counter (Packard, 
Cobra Auto-Gamma); the counting efficiency 
was 74%. Dependence of binding on the 
125concentration of I-ET-1, in the absence and in 
the presence of 1 ìM of unlabeled ET-1, was 
determined as described above. Displacement 
of the radioligand from its binding sites was 
evaluated by incubating the monocytes with a 
125 10constant concentration of I-ET-1 (5 x 10 M) 
and increasing concentrations of unlabeled ET-1 
and processed as mentioned above. Specific 
binding was defined as total binding minus non-
specific binding that occurred in the presence of 
an excess (1 ìM) of unlabeled ET-1. The 
dissociation constant, Kd, and the maximal 
binding capacity, Bmax, were determined using 
the Ligand program developed by Munson and 
9Rodbard.  
Chemotaxis assay
Chemotaxis of monocytes was assayed by the 
8method described previously  in a 24-well-plate 
with cell culture inserts. The bottom wells (500 
ìL) contained various concentrations of ET-1 
dissolved in RPMI 1640 medium. Monocytes 
were added to the upper wells (cell culture insert) 
5in a volume of 250 ìL which contained 1.25 x 10  
0cells per well. After 60 min of incubation at 37 C in 
a humidified incubator with air and 5% CO , the 2
upper wells were removed and the non-migrated 
cells, i.e., the cells that did not settle on the 
membrane-bottom of the well, were removed 
gently by sucking up with a pipette. Cells on the 
membrane were carefully washed with PBS to 
remove the rest of the cells which were not firmly 
attached. They were then fixed with methanol 
and stained with Mayer's hemalum solution for 7 
min. The cells firmly attached to the membrane 
were counted with a 12.5-fold-ocular and a 10-
fold-objective with four counting grids. Five areas 
containing 4 grids were counted per well and 
averaged. The mean variation among the 
counted field was 12 ± 6% for the test solutions 
and 19 ± 8% for the controls. Chemotaxis activity 
is expressed as chemotactic index, CI, defined 
as the ratio of the number of cells migrating in the 
response to ET-1 to the number of cells migrating 
when only medium was in the lower chamber, 
which was also the control. Receptor subtype 
was evaluated by incubating the monocytes with 
specific endothelin receptor antagonists BQ-123 
(0.1 and 10 ìM), BE-18257B (1 ìM) or IRL-1038 
(1 ìM) for 60 min followed by determination of 
chemotaxis toward ET-1 as described above.
RESULTS
The binding of 125I-ET-1 to monocytes was time 
dependent; it increased progressively up to 60 
min and reached an apparent steady state 
thereafter (Fig. 1); non-specific binding varied 
between 30% and 50% of total binding over the 
time range.
125Binding of I-ET-1 increased with 
125increasing concentrations of I-ET-1, the 
kinetics of which appeared to deviate from the 
hyperbolic form of a typical concentration curve 
(Fig. 2). Analysis of the binding data by the 
Ligand program (Fig. 2 inset) revealed 
the presence of two distinct subclasses of 
binding sites. One had a high affinity and low 
binding capacity for ET-1, the apparent Kd was 
510.3 pM and the Bmax 0.027 fmol/1.5 x 10  cells. 
The second subclass of binding site had low 
affinity and high binding capacity for ET-1; the 
apparent Kd and Bmax values were 3.5 nM and 
50.63 fmol/1.5 x 10  cells, respectively. 
Unlabeled ET-1 competitively displaced  
125I-ET-1 from its binding sites on the monocyte; 
the calculated inhibitor constants, Kis, [(EC /(1 + 50
L/K)] for the two binding sites, calculated by the 
Ligand program, were 70 pM and 3.6 nM, 
respectively (Fig. 3).
Chemotaxis of monocytes toward 
-10 -6varying concentrations, 10 –10 M, of ET-1 and 
in the presence of 2 fixed concentrations of the 
specific ET  receptor antagonist, BQ-123, A
decreased migration (Fig. 4). At 0.1 ìM of BQ-
123 the decrease in CI ranged from 22% to 29%, 
at 10 ìM the decrease ranged from 42% to 54%. 
Another ET  receptor antagonist, BE-18257B (1 A
ìM), also inhibited monocyte migration; the 
decrease in CI ranged from 20% to 35%. The ET  B
receptor antagonist IRL-1038 (1 ìM) reduced 
migration; the decrease in the CI ranged from 8% 
to 28% (Fig. 5). 
 
 
125Figure 1 Specific Binding of I-ET-1 to Human Blood Monoctye As a Function of Time
-10 125 0Freshly isolated monoctyes were incubated with 3 x 10  M I-ET-1 at 37 C for the times indicated. 
Specific binding (SB) was obtained by substracting non-specific binding (NSB) that occurred in the 
presence of 1 ìM unlabeled ET-1 from total binding (TB). Each point is the mean ± SD of triplicate 
experiments.
Figure 2 Saturable Binding of 125I-ET-1 to Human Blood Monocyte
0 125Freshly isolated monocytes were incubated at 37 C for 60 min with various concentration of I-ET-1. 
Non-specific binding in the presence of 1 ìM unlabeled ET-1 ranged from 30-50% of total binding. 
Each point is the mean ± SD of triplicate experiments. Inset shows the Scatchard plot of the binding 
data
DISCUSSION
Monocyte attachment to the endothelium and 
migration into the intimal space of the blood 
vessel are construed as the earliest events in the 
chain of reactions leading to atherosclerotic 
changes of the vasculature. In patients with risk 
factors for atherosclerosis the circulating levels 
10,11of ET-1 are increased.  Our previous study 
indicated that ET-1 possesses chemotactic 
activity for human blood monocytes. The 
underlying mechanism triggering migration was 
2+ 2+through Ca  influx since Ca  antagonists 
8reduced migration.  In the present study we used 
125I-ET-1 to detect binding sites for ET-1 on the 
monocyte. The results clearly demonstrate, for 
the first time, the occurrence of two distinct 
subpopulations of binding sites for ET-1 on 
freshly isolated human blood monocytes. Recent 
studies have reported that at least two subtypes 
of binding sites for ET-1  isopeptides exist on the 
12membrane endothelial cells.  The binding of ET-
1 to blood monocytes was reversible and the 
affinity of the binding site with the low Kd lies in 
the pM range agreeing with the concentration of 
ET-1 in plasma of normal individuals (0.1-7.98 
13pM).  The high affinity component possessed 
108 sites and the low affinity component 2,529 
125Figure 3 Displacement of I-ET-1 from Its Binding Sites on Monocytes by Unlabeled ET-1
5 125 -101.5 x 10  freshly isolated monoctyes were incubated with I-ET-1 (5 x 10 M)  in a total volume of 
200 ìl in the absence and presence of increasing concentrations of unlabeled ET-1. Each point is 
the mean ± SD of triplicate experiment.
Figure 4 Influence of ET  Receptor Antagonist BQ-123 on the Chemotaxis of Monocytes A
The monocytes were pretreated with two different concentrations of BQ-123 for 60 min prior to 
-10 6the chemotaxis assay. The concentration range of ET-1 was 10 M-10 M. The values are means 
and the vertical bars SDs from 3 separate experiments.
Figure 5 Influence of ET  Receptor Antagonist BQ-1825B, and ET  Receptor Antagonist IRL-1038 A B
on the Chemotaxis of Monocytes
Treatment of monocytes with the receptor antagonists and the chemotaxis assay were 
performed as described in the legend for Fig.3. The values are means and the vertical bars 
sites per monocyte. The binding affinity of ET-1 to 
14,15cells from different tissues  and the binding 
affinity of ET-1 to monocytes is almost similar, 
ranging from pM to nM. To date three ET 
receptors, ET , ET  and ET , have been identified A B C
and several ET receptors antagonists have 
16-18studied.  Using the chemotaxis as a response 
of monocytes to ET-1 and specific ET-1 receptor 
antagonists our study shows that at least two 
receptor subtypes are activated on the monocyte 
during ET-1 stimulus; one is the ET  receptor A
which is affected by the antagonist BQ-123 and 
BE-18257 and the second one is the ET  B
receptor which is affected by the antagonist IRL-
1038. The consequence of receptor antagonism 
was decrease in the number of monocytes 
migrating in response to the chemotactic 
stimulus of ET-1. Apparently both receptors 
contribute to the chemotaxis process. 
Considering the affinities of the two receptor 
subtypes and the decrease in monocyte 
migration affected by the receptor antagonists, it 
is likely that the high affinity component is the ET  A
receptor and the binding component with the low 
affinity the ET  receptor, since ET-1 was bound B
with a higher affinity to the ET  than to the ET  A B
receptor. The data also suggest that the ET  A
receptors exercises a greater influence on 
chemotaxis than the ET  recetors albeit their B
greater abundance. The different affinities and 
capacities of the endothelin receptors suggest 
that endothelin isopeptides are involved in a wide 
range of physiological and pathological events in 
19an organism or cells, as well as in monocytes.  In 
conclusion, our data provide evidence for the 
occurrence of specific receptors for ET-1 on 
human blood monocytes. Redistribution or a 
change in directional orientation of these 
receptors by ET-1 probably enhances monocyte 
migration.
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